| Year |
Citation |
Score |
| 2016 |
Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget. PMID 27192116 DOI: 10.18632/Oncotarget.9326 |
0.334 |
|
| 2016 |
Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, Tailor R, Pidikiti R, Guha CP, Hahn SM, Krishnan S, Hodge JW. Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. International Journal of Radiation Oncology, Biology, Physics. 95: 120-30. PMID 27084634 DOI: 10.1016/j.ijrobp.2016.02.022 |
0.314 |
|
| 2016 |
Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. PMID 26862729 DOI: 10.18632/Oncotarget.7180 |
0.368 |
|
| 2015 |
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, ... ... Hodge JW, et al. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology. 6: 588. PMID 26635802 DOI: 10.3389/Fimmu.2015.00588 |
0.342 |
|
| 2015 |
Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, Madan RA, Heery CR, Balint JP, Jones FR, Schlom J. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget. PMID 26374823 DOI: 10.18632/oncotarget.5181 |
0.347 |
|
| 2015 |
Kwilas AR, Ardiani A, Dirmeier U, Wottawah C, Schlom J, Hodge JW. A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model. Oncotarget. 6: 28194-210. PMID 26317648 DOI: 10.18632/oncotarget.4442 |
0.374 |
|
| 2015 |
Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell & Microenvironment. 2. PMID 26005708 DOI: 10.14800/ccm.677 |
0.342 |
|
| 2015 |
Garnett-Benson C, Hodge JW, Gameiro SR. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Seminars in Radiation Oncology. 25: 46-53. PMID 25481266 DOI: 10.1016/j.semradonc.2014.07.002 |
0.333 |
|
| 2015 |
Kwilas AR, Ardiani A, Dirmeier U, Wottawah C, Schlom J, Hodge JW. A poxviral-based cancer vaccine targeting the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model Oncotarget. 6: 28194-28210. DOI: 10.18632/oncotarget.4442 |
0.373 |
|
| 2014 |
Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, ... ... Hodge JW, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 3: e955691. PMID 25941621 DOI: 10.4161/21624011.2014.955691 |
0.324 |
|
| 2014 |
Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. Journal of Translational Medicine. 12: 294. PMID 25388653 DOI: 10.1186/s12967-014-0294-y |
0.34 |
|
| 2014 |
Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunology Research. 2: 1090-102. PMID 25092771 DOI: 10.1158/2326-6066.CIR-14-0076 |
0.372 |
|
| 2014 |
Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of radiotherapy: new paradigms. Radiation Research. 182: 123-5. PMID 25036983 DOI: 10.1667/Rr13849.1 |
0.367 |
|
| 2014 |
Wattenberg MM, Fahim A, Ahmed MM, Hodge JW. Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiation Research. 182: 126-38. PMID 24960415 DOI: 10.1667/RR13374.1 |
0.329 |
|
| 2014 |
Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Therapeutic cancer vaccines Advances in Cancer Research. 121: 67-112. PMID 24889529 DOI: 10.1016/B978-0-12-800249-0.00002-0 |
0.398 |
|
| 2014 |
Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunology Research. 2: 133-41. PMID 24778277 DOI: 10.1158/2326-6066.CIR-13-0108 |
0.396 |
|
| 2014 |
Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC. Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proceedings of the National Academy of Sciences of the United States of America. 111: E1749-58. PMID 24733910 DOI: 10.1073/Pnas.1314722111 |
0.319 |
|
| 2014 |
Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang KY, Hodge JW. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines. Vaccine. 32: 3223-31. PMID 24731809 DOI: 10.1016/j.vaccine.2014.04.008 |
0.435 |
|
| 2014 |
Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW. Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. Cancer Research. 74: 1945-57. PMID 24520078 DOI: 10.1158/0008-5472.CAN-13-2045 |
0.379 |
|
| 2014 |
Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 5: 403-16. PMID 24480782 DOI: 10.18632/Oncotarget.1719 |
0.321 |
|
| 2013 |
Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunology Research. 1: 280-4. PMID 24777964 DOI: 10.1158/2326-6066.CIR-13-0141 |
0.363 |
|
| 2013 |
Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C. Immunological targeting of tumor cells undergoing an epithelialmesenchymal transition via a recombinant brachyury-yeast vaccine Oncotarget. 4: 1777-1790. PMID 24125763 DOI: 10.18632/Oncotarget.1295 |
0.383 |
|
| 2013 |
Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. Plos One. 8: e70417. PMID 23894654 DOI: 10.1371/Journal.Pone.0070417 |
0.354 |
|
| 2013 |
Gameiro SR, Jammeh ML, Hodge JW. Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. Expert Review of Vaccines. 12: 617-29. PMID 23750792 DOI: 10.1586/erv.13.40 |
0.345 |
|
| 2013 |
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International Journal of Cancer. Journal International Du Cancer. 133: 624-36. PMID 23364915 DOI: 10.1186/2051-1426-1-S1-P91 |
0.331 |
|
| 2013 |
Schlom J, Hodge JW, Palena C, Greiner JW, Tsang KY, Farsaci B, Madan RA, Gulley JL. Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. 309-331. DOI: 10.1016/B978-0-12-394296-8.00020-8 |
0.381 |
|
| 2012 |
Kwilas AR, Donahue RN, Bernstein MB, Hodge JW. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Frontiers in Oncology. 2: 104. PMID 22973551 DOI: 10.3389/fonc.2012.00104 |
0.391 |
|
| 2012 |
Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Seminars in Oncology. 39: 323-39. PMID 22595055 DOI: 10.1053/j.seminoncol.2012.02.006 |
0.36 |
|
| 2012 |
Gameiro SR, Caballero JA, Hodge JW. Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing. Cancer Biotherapy & Radiopharmaceuticals. 27: 23-35. PMID 22316209 DOI: 10.1089/cbr.2012.1203 |
0.305 |
|
| 2012 |
Hodge JW, Sharp HJ, Gameiro SR. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biotherapy & Radiopharmaceuticals. 27: 12-22. PMID 22283603 DOI: 10.1089/cbr.2012.1202 |
0.397 |
|
| 2012 |
Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy International Journal of Cancer. 130: 1948-1959. PMID 21633954 DOI: 10.1002/ijc.26219 |
0.408 |
|
| 2011 |
Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunology, Immunotherapy : Cii. 60: 1227-42. PMID 21544650 DOI: 10.1007/s00262-011-1020-8 |
0.394 |
|
| 2010 |
Ardiani A, Higgins JP, Hodge JW. Vaccines based on whole recombinant Saccharomyces cerevisiae cells Fems Yeast Research. 10: 1060-1069. PMID 20707820 DOI: 10.1111/j.1567-1364.2010.00665.x |
0.389 |
|
| 2010 |
Farsaci B, Sabzevari H, Higgins JP, Di Bari MG, Takai S, Schlom J, Hodge JW. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine International Journal of Cancer. 127: 1603-1613. PMID 20091862 DOI: 10.1002/ijc.25177 |
0.393 |
|
| 2010 |
Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunology, Immunotherapy : Cii. 59: 397-408. PMID 19756595 DOI: 10.1007/S00262-009-0759-7 |
0.353 |
|
| 2009 |
Higgins JP, Bernstein MB, Hodge JW. Enhancing immune responses to tumor-associated antigens. Cancer Biology & Therapy. 8: 1440-9. PMID 19556848 DOI: 10.4161/cbt.8.15.9133 |
0.368 |
|
| 2009 |
Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer Expert Opinion On Investigational Drugs. 18: 1001-1011. PMID 19548854 DOI: 10.1517/13543780902997928 |
0.389 |
|
| 2009 |
Hodge JW, Higgins J, Schlom J. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen Vaccine. 27: 4475-4482. PMID 19450631 DOI: 10.1016/j.vaccine.2009.05.017 |
0.386 |
|
| 2008 |
Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers: Opportunities and challenges Oncology. 22: 1064-1070. PMID 18777956 |
0.319 |
|
| 2008 |
Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, Quick D, Franzusoff A, Greiner JW, Schlom J, Hodge JW. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4316-25. PMID 18594015 DOI: 10.1158/1078-0432.Ccr-08-0393 |
0.419 |
|
| 2008 |
Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4241-9. PMID 18594006 DOI: 10.1158/1078-0432.CCR-08-0335 |
0.312 |
|
| 2008 |
Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3536-44. PMID 18519787 DOI: 10.1158/1078-0432.CCR-07-4025 |
0.356 |
|
| 2008 |
Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunology, Immunotherapy : Cii. 57: 1173-83. PMID 18256832 DOI: 10.1007/s00262-008-0449-x |
0.421 |
|
| 2008 |
Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostböck S, Sabzevari H, Schlom J, Hodge JW. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine. 26: 509-21. PMID 18155327 DOI: 10.1016/J.Vaccine.2007.11.033 |
0.332 |
|
| 2007 |
Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy Critical Reviews in Immunology. 27: 451-462. PMID 18197807 DOI: 10.1615/CRITREVIMMUNOL.V27.I5.40 |
0.436 |
|
| 2007 |
Arlen PM, Madan RA, Hodge JW, Schlom J, Gulley JL. Combining Vaccines with Conventional Therapies for Cancer. Update On Cancer Therapeutics. 2: 33-39. PMID 17948067 DOI: 10.1016/j.uct.2007.04.004 |
0.389 |
|
| 2007 |
Sharp HJ, Wansley EK, Garnett CT, Chakraborty M, Camphausen K, Schlom J, Hodge JW. Synergistic antitumor activity of immune strategies combined with radiation. Frontiers in Bioscience : a Journal and Virtual Library. 12: 4900-10. PMID 17569618 DOI: 10.2741/2436 |
0.316 |
|
| 2007 |
Kudo-Saito C, Garnett CT, Wansley EK, Schlom J, Hodge JW. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. Cancer Immunology, Immunotherapy : Cii. 56: 1897-910. PMID 17503041 DOI: 10.1007/s00262-007-0332-1 |
0.377 |
|
| 2007 |
Chakraborty M, Schlom J, Hodge JW. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses Cancer Immunology, Immunotherapy. 56: 1471-1484. PMID 17318654 DOI: 10.1007/s00262-007-0291-6 |
0.412 |
|
| 2007 |
Arlen PM, Madan RA, Hodge JW, Schlom J, Gulley JL. Combining vaccines with conventional therapies for cancer Update On Cancer Therapeutics. 2: 33-39. DOI: 10.1016/j.uct.2007.04.004 |
0.389 |
|
| 2007 |
Orentas R, Hodge JW, Johnson BD. Cancer Vaccines and Tumor Immunity Cancer Vaccines and Tumor Immunity. 1-334. DOI: 10.1002/9780470170113 |
0.373 |
|
| 2006 |
Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Advances in Cancer Research. 95: 115-45. PMID 16860657 DOI: 10.1016/S0065-230X(06)95004-0 |
0.362 |
|
| 2006 |
Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines Vaccine. 24: 4975-4986. PMID 16621183 DOI: 10.1016/j.vaccine.2006.03.042 |
0.431 |
|
| 2006 |
Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW. TRICOM vector based cancer vaccines. Current Pharmaceutical Design. 12: 351-61. PMID 16454749 DOI: 10.2174/138161206775201929 |
0.428 |
|
| 2006 |
Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J. Costimulatory molecules as adjuvants for immunotherapy Frontiers in Bioscience. 11: 788-803. PMID 16146771 DOI: 10.2741/1837 |
0.402 |
|
| 2005 |
Yang S, Hodge JW, Grosenbach DW, Schlom J. Vaccines with enhanced costimulation maintain high avidity memory CTL Journal of Immunology. 175: 3715-3723. PMID 16148117 DOI: 10.4049/jimmunol.175.6.3715 |
0.366 |
|
| 2005 |
Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors Clinical Cancer Research. 11: 4533-4544. PMID 15958639 DOI: 10.1158/1078-0432.CCR-04-2237 |
0.432 |
|
| 2005 |
Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. Journal of Immunology (Baltimore, Md. : 1950). 174: 5994-6004. PMID 15879092 DOI: 10.4049/jimmunol.174.10.5994 |
0.335 |
|
| 2005 |
Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses Clinical Cancer Research. 11: 2416-2426. PMID 15788693 DOI: 10.1158/1078-0432.CCR-04-1380 |
0.434 |
|
| 2005 |
Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 720-31. PMID 15613691 DOI: 10.1200/JCO.2005.10.206 |
0.369 |
|
| 2004 |
Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW. Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation Developments in Biologicals. 116: 27-47. PMID 15603182 |
0.316 |
|
| 2004 |
Garnett CT, Palena C, Chakraborty M, Chakarborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Research. 64: 7985-94. PMID 15520206 DOI: 10.1158/0008-5472.CAN-04-1525 |
0.364 |
|
| 2004 |
Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: Implications for intratumoral vaccine therapy Cancer Gene Therapy. 11: 665-680. PMID 15354200 DOI: 10.1038/sj.cgt.7700741 |
0.359 |
|
| 2004 |
Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Research. 64: 4328-37. PMID 15205348 DOI: 10.1158/0008-5472.Can-04-0073 |
0.415 |
|
| 2004 |
Kudo-Saito C, Schlom J, Hodge JW. Intratumoral Vaccination and Diversified Subcutaneous/Intratumoral Vaccination with Recombinant Poxviruses Encoding a Tumor Antigen and Multiple Costimulatory Molecules Clinical Cancer Research. 10: 1090-1099. PMID 14871989 DOI: 10.1158/1078-0432.CCR-03-0145 |
0.337 |
|
| 2003 |
Hodge JW, Poole DJ, Aarts WM, Yafal AG, Gritz L, Schlom J. Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses Cancer Research. 63: 7942-7949. PMID 14633725 |
0.41 |
|
| 2003 |
Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 170: 6338-47. PMID 12794167 DOI: 10.4049/Jimmunol.170.12.6338 |
0.316 |
|
| 2003 |
Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity Clinical Cancer Research. 9: 1837-1849. PMID 12738742 |
0.375 |
|
| 2002 |
Hodge JW, Grosenbach DW, Schlom J. Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity Cancer Detection and Prevention. 26: 275-291. PMID 12430632 DOI: 10.1016/S0361-090X(02)00095-8 |
0.413 |
|
| 2002 |
Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity Cancer Research. 62: 5770-5777. PMID 12384537 |
0.32 |
|
| 2002 |
Schmitz J, Reali E, Hodge JW, Patel A, Davis G, Schlom J, Greiner JW. Identification of an interferon-γ-inducible carcinoembryonic antigen (CEA) CD8+ T-cell epitope, which mediates tumor killing in CEA transgenic mice Cancer Research. 62: 5058-5064. PMID 12208761 |
0.382 |
|
| 2001 |
Shankar P, Schlom J, Hodge JW. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3) Vaccine. 20: 744-755. PMID 11738738 DOI: 10.1016/S0264-410X(01)00409-1 |
0.357 |
|
| 2001 |
Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects Cancer Research. 61: 4497-4505. PMID 11389081 |
0.406 |
|
| 2000 |
Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Gómez Yafal A, Gritz L, Schlom J. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules Journal of the National Cancer Institute. 92: 1228-1239. PMID 10922408 DOI: 10.1093/JNCI/92.15.1228 |
0.309 |
|
| 2000 |
Freund YR, Mirsalis JC, Fairchild DG, Brune J, Hokama LA, Schindler-Horvat J, Tomaszewski JE, Hodge JW, Schlom J, Kantor JA, Tyson CA, Donohue SJ. Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. International Journal of Cancer. Journal International Du Cancer. 85: 508-17. PMID 10699923 DOI: 10.1002/(SICI)1097-0215(20000215)85:4<508::AID-IJC11>3.0.CO;2-D |
0.333 |
|
| 1999 |
Schlom J, Hodge JW. The diversity of T-cell co-stimulation in the induction of antitumor immunity Immunological Reviews. 170: 73-84. PMID 10566143 DOI: 10.1111/j.1600-065X.1999.tb01330.x |
0.375 |
|
| 1999 |
Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines Cancer Research. 59: 5106-5111. PMID 10537283 |
0.347 |
|
| 1999 |
Lorenz MGO, Kantor JA, Schlom J, Hodge JW. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L) Human Gene Therapy. 10: 1095-1103. PMID 10340542 DOI: 10.1089/10430349950018094 |
0.322 |
|
| 1999 |
Lorenz MGO, Kantor JA, Schlom J, Hodge JW. Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus Human Gene Therapy. 10: 623-631. PMID 10094205 DOI: 10.1089/10430349950018698 |
0.353 |
|
| 1999 |
Kalus RM, Kantor JA, Gritz L, Yafal AG, Mazzara GP, Schlom J, Hodge JW. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation Vaccine. 17: 893-903. PMID 10067696 DOI: 10.1016/S0264-410X(98)00275-8 |
0.407 |
|
| 1998 |
Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW. Cancer vaccine development. Expert Opinion On Investigational Drugs. 7: 1439-52. PMID 15992042 DOI: 10.1517/13543784.7.9.1439 |
0.347 |
|
| 1997 |
Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses Vaccine. 15: 759-768. PMID 9178479 DOI: 10.1016/S0264-410X(96)00238-1 |
0.338 |
|
| 1997 |
Uzendoski K, Kantor JA, Abrams SI, Schlom J, Hodge JW. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumor responses Human Gene Therapy. 8: 851-860. PMID 9143911 DOI: 10.1089/Hum.1997.8.7-851 |
0.31 |
|
| 1997 |
Abrams SI, Hodge JW, McLaughlin JP, Steinberg SM, Kantor JA, Schlom J. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine Journal of Immunotherapy. 20: 48-59. PMID 9101413 DOI: 10.1097/00002371-199701000-00005 |
0.372 |
|
| 1997 |
Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7 Journal of Immunotherapy. 20: 38-47. PMID 9101412 DOI: 10.1097/00002371-199701000-00004 |
0.313 |
|
| 1996 |
Hodge JW, Schlom J. Carcinoembryonic antigen as a target for cancer vaccines Cancer Immunology Immunotherapy. 43: 127-134. PMID 9001565 DOI: 10.1007/s002620050313 |
0.375 |
|
| 1995 |
Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a Recombinant Vaccinia Virus Containing the Gene for the Costimulatory Molecule B7 and a Recombinant Vaccinia Virus Containing a Tumor-associated Antigen Gene Results in Enhanced Specific T-Cell Responses and Antitumor Immunity Cancer Research. 55: 3598-3603. PMID 7543017 |
0.317 |
|
| Show low-probability matches. |